Dynamic Technology Lab Private Ltd Makes New $511,000 Investment in Illumina, Inc. $ILMN

Dynamic Technology Lab Private Ltd bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,383 shares of the life sciences company’s stock, valued at approximately $511,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Empowered Funds LLC increased its stake in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after acquiring an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Illumina during the second quarter worth about $621,000. AE Wealth Management LLC increased its stake in shares of Illumina by 5.8% during the second quarter. AE Wealth Management LLC now owns 30,381 shares of the life sciences company’s stock valued at $2,899,000 after buying an additional 1,664 shares during the period. Aviva PLC lifted its position in shares of Illumina by 7.0% in the 2nd quarter. Aviva PLC now owns 116,925 shares of the life sciences company’s stock worth $11,156,000 after purchasing an additional 7,609 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the period. Institutional investors own 89.42% of the company’s stock.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research reports. Piper Sandler dropped their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. UBS Group reiterated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Finally, Guggenheim lifted their target price on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Stock Down 1.6%

Shares of NASDAQ ILMN opened at $122.35 on Wednesday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a 50 day moving average price of $133.96 and a 200 day moving average price of $119.69. The firm has a market capitalization of $18.71 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 2.38 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.